Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
CryptoSlate3h agoUpdated 3h ago
Smart Read
Enlivex pledged commercially reasonable efforts to hold the shareholder vote within 60 days, while the second $400 million remains optional. The post Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug appeared first on CryptoSlate....
Coins in this story
Discussion
Related stories
Decrypt4h ago
US Treasury Sanctions Iranian Firms Taking Bitcoin for Hormuz Passage
OFAC sanctioned two Iranian firms including Hormuz Safe, which “accepts payment in Bitcoin and other digital assets.”...
CoinDesk4h ago
Crypto faces 3 barriers to next bull run, STS Digital CEO says
Institutional options selling, AI and delayed U.S. crypto regulation are weighing on bitcoin, according to STS Digital CEO Maxime Seiler....
CoinDesk5h ago
Circle secures New York trust charter as crypto regulatory push accelerates
The approval lets the USDC issuer offer fiduciary and custody services under New York banking law....
KryptoKite aggregates and summarises third-party crypto news. This is informational content, not investment advice. KryptoKite does not recommend buying or selling any asset.